A5102992111- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Head and Neck Cancer Studies
- Retinoids in leukemia and cellular processes
- Genomic variations and chromosomal abnormalities
- Genetic factors in colorectal cancer
- Cancer therapeutics and mechanisms
- Cancer-related Molecular Pathways
- Oral Health Pathology and Treatment
- Antioxidant Activity and Oxidative Stress
- Neuroendocrine Tumor Research Advances
- Radiomics and Machine Learning in Medical Imaging
- Cholangiocarcinoma and Gallbladder Cancer Studies
- SARS-CoV-2 and COVID-19 Research
- Cancer Genomics and Diagnostics
- Estrogen and related hormone effects
- Cancer Research and Treatments
- Tracheal and airway disorders
- HER2/EGFR in Cancer Research
- interferon and immune responses
- Cancer-related gene regulation
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Brain Metastases and Treatment
- Molecular Biology Techniques and Applications
University of Cambridge
2021-2024
Kyung Hee University
2021
The University of Texas MD Anderson Cancer Center
1994-2018
Imperial College London
2017
Ajou University
2017
National Cancer Center
2004-2006
Georgetown University Medical Center
2002
West Virginia University
2002
Georgetown University
2002
The University of Texas Health Science Center at Houston
2001
Retinoids are effective in the treatment and prevention of certain human cancers. Most their actions thought to result from changes gene expression mediated by nuclear retinoic acid receptors retinoid X receptors. We conducted a study determine whether these was altered premalignant oral lesions and, if so, could be restored with isotretinoin.
The mechanisms that cause chemoresistance in non-small-cell lung cancer (NSCLC) patients have yet to be clearly elucidated. Paclitaxel is a tubulin-disrupting agent binds preferentially beta-tubulin. Tubulins are guanosine triphosphate (GTP)-binding proteins. Beta-tubulin GTPase, whereas alpha-tubulin has no enzyme activity. We reasoned polymerase chain reaction (PCR) and DNA sequencing of the beta-tubulin gene could reveal more information regarding connection between mutations primary...
PURPOSE: This trial was designed to determine the maximum-tolerated dose, toxicity, and pharmacology of oral green tea extract (GTE) once daily or three times daily. PATIENTS AND METHODS: Cohorts more adult cancer patients were administered GTE with water after meals one for 4 weeks, a maximum 6 months, depending on disease response patient tolerance. Pharmacokinetic analyses encouraged but optional. RESULTS: Dose levels 0.5 5.05 g/m 2 qd 1.0 2.2 tid explored. A total 49 studied. Patient...
New prognostic factors are needed to guide the treatment of patients with non-small-cell lung cancer. We evaluated value altered expression ABH blood-group antigens, which has been implicated in multistep process carcinogenesis and tumor progression.
The authors retrospectively reviewed data regarding 14 patients with sarcomatoid carcinomas of the lung seen and treated at M. D. Anderson Cancer Center from 1955 to 1986. following were histologic criteria for inclusion in study: (1) concurrent presence malignant epithelial spindle cell components, (2) positive immunoreactivity antikeratin antibody or ultrastructural demonstration differentiation tumors which component was inconspicuous. For most frequent pattern fibrous histiocytoma,...
Cyclooxygenase (Cox) is the main target enzyme for nonsteroidal antiinflammatory drugs that have been shown to suppress carcinogenesis in both experimental models and epidemiologic studies.To evaluate its utility as an intermediate biomarker bronchial chemoprevention trials, authors examined Cox 1 2 expression normal premalignant epithelial cells nonsmall cell lung carcinoma (NSCLC) samples using immunohistochemical staining technique. Included current study were 101 NSCLC 77 biopsy obtained...
Background. The authors retrospectively analyzed 87 patients with malignant thymoma treated at M. D. Anderson Cancer Center between 1951 and 1990. analysis examined the clinical stages, histologic types, treatment modalities attempted to determine if chemotherapy had an impact on survival. Methods. were divided into three groups by their year of modality. Patients 1975 in Group I; 1976 1980 II; 1981 1990 III. Most (18 [72%] 16 [62%] 18 [50%] III) surgical resection alone or radiotherapy....
PURPOSE: Retinoids are pivotal in the growth and differentiation of certain epithelial tissues, interacting with nuclear retinoid receptors (the retinoic acid [RARs] X [RXRs]), which function as transcription factors. RAR-beta mRNA is undetectable by situ hybridization (ISH) 50% non–small-cell lung cancers (NSCLC). RAR-β may suppress tumorigenicity. Therefore, we hypothesized that loss expression gene stage I NSCLC a prognostic factor poor clinical outcome. PATIENTS AND METHODS: We...
To assess the prognostic value of DNA ploidy in non-small cell lung cancer (NSCLC), we performed a flow cytometric study using paraffin-embedded archival material from 158 patients who underwent surgical resection between 1980 and 1982. Single-variable histograms were examined results these correlated with clinicopathologic characteristics outcome. Histograms that could be analyzed obtained 146 cases, which 85 (58%) aneuploid 61 (42%) diploid. Survival analysis showed diploid squamous...
BACKGROUND Surveillance, Epidemiology, and End Results (SEER) data for the years 1973–1992 documented that patients age < 50 presented with more advanced disease. Because of increase in incidence rate lung adenocarcinoma past few decades presentation disease young patients, this study was performed to determine whether differences survival exist between younger older METHODS The authors reviewed experience University Texas M. D. Anderson Cancer Center 1985–1994, encompassing 157 40 4097...
PURPOSE: The combination of cisplatin, etoposide, and paclitaxel was studied in patients with extensive small-cell lung cancer a phase I component followed by II trial to determine the maximum-tolerated dose (MTD), characterize toxicity, estimate response median survival rates. PATIENTS AND METHODS: Forty-one were treated between October 1993 April 1997. Doses for initial cohort cisplatin 75 mg/m 2 on day 1, etoposide 80 /d days 1 3, 130 over 3 hours. Cycles repeated every weeks up six...